Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) shot up 1% during trading on Monday . The company traded as high as $3.10 and last traded at $3.10. 27,562 shares changed hands during mid-day trading, a decline of 18% from the average session volume of 33,586 shares. The stock had previously closed at $3.07.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Alpha Tau Medical in a report on Friday, November 22nd.
View Our Latest Analysis on DRTS
Alpha Tau Medical Trading Up 0.6 %
The stock has a market capitalization of $218.16 million, a PE ratio of -7.26 and a beta of 0.85. The company has a current ratio of 10.99, a quick ratio of 11.60 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average price of $2.50 and a 200-day moving average price of $2.34.
Institutional Trading of Alpha Tau Medical
A number of large investors have recently added to or reduced their stakes in DRTS. Caprock Group LLC bought a new position in shares of Alpha Tau Medical during the 2nd quarter valued at approximately $59,000. Aptus Capital Advisors LLC lifted its stake in Alpha Tau Medical by 83.7% in the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company's stock valued at $56,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Financial Guidance Group Inc. grew its holdings in Alpha Tau Medical by 83.7% during the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company's stock valued at $56,000 after purchasing an additional 10,000 shares during the period. Hedge funds and other institutional investors own 2.65% of the company's stock.
Alpha Tau Medical Company Profile
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
See Also
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
